.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,404,702

« Back to Dashboard

Claims for Patent: 8,404,702

Title:Pharmaceutical formulations:salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diaza-sp- iro[4.5]decan-2-one and treatment methods using the same
Abstract: Pharmaceutical formulations containing salts of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-ph- enyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, are disclosed. Disclosed also are methods of treatment utilizing such dosage forms.
Inventor(s): Qiu; Zhihui (Bridgewater, NJ), Reyderman; Larisa (Watchung, NJ)
Assignee: Opko Health, Inc. (Miami, FL)
Application Number:13/184,926
Patent Claims: 1. A method for treatment of acute onset nausea and/or emesis in a mammal comprising administering to the mammal a pharmaceutical formulation comprising a crystalline salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-ph- enyl-1,7-diazaspiro[4,5]decan-2-one, and a pharmaceutically acceptable excipient.

2. The method of claim 1, wherein the nausea and/or emesis arises from chemotherapy, radiation therapy, or during a post-operative recovery period.

3. The method of claim 1, wherein said formulation comprises 5, 10, 25, 50, 100 or 200 mg of the crystalline hydrochloride monohydrate salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-ph- enyl-1,7-diazaspiro[4,5]decan-2-one.

4. The method of claim 1, wherein said formulation is incorporated into an oral dosage form.

5. A method for the treatment of acute onset emesis and/or acute onset nausea along with chemotherapy by administering a combination comprising a pharmaceutical formulation comprising a crystalline salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-ph- enyl-1,7-diazaspiro[4,5]decan-2-one and a chemotherapeutic agent to a patient in need of chemotherapy.

6. The method of claim 5, wherein said formulation is administered contemporaneously or simultaneously with the chemotherapeutic agent to the patient in need of chemotherapy, thereby providing therapy for acute onset emesis and/or acute onset nausea along with chemotherapy.

7. The method of claim 6, wherein the formulation is administered contemporaneously with the chemotherapeutic agent.

8. The method of claim 7, wherein the formulation is administered contemporaneously with the chemotherapeutic agent such that the formulation is administered before administration of the chemotherapeutic agent.

9. The method of claim 7, wherein the formulation is administered contemporaneously with the chemotherapeutic agent such that the formulation is administered during administration of the chemotherapeutic agent.

10. The method of claim 7, wherein the formulation is administered contemporaneously with the chemotherapeutic agent such that the formulation is administered after administration of the chemotherapeutic agent.

11. The method of claim 1, wherein the salt is a hydrochloride salt.

12. The method of claim 11, wherein the salt is a monohydrate hydrochloride.

13. The method of claim 1, wherein the pharmaceutically acceptable excipient is selected from at least one of the group consisting of lactose, microcrystalline cellulose, croscarmellose sodium, pregelatinized starch, and magnesium stearate.

14. The method of claim 1, wherein the formulation is a granular formulation.

15. The method of claim 1, wherein the pharmaceutical formulation comprises 5-200 mg of the crystalline salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-ph- enyl-1,7-diazaspiro[4,5]decan-2-one per dosage form.

16. The method of claim 1, wherein the pharmaceutical formulation contains 200 mg of the crystalline salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-ph- enyl-1,7-diazaspiro[4,5]decan-2-one.

17. A method of providing therapy to a patient in need of treatment thereof for acute onset emesis and/or acute onset nausea along with chemotherapy by administering a combination comprising a pharmaceutical formulation comprising a crystalline hydrochloride monohydrate salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-ph- enyl-1,7-diazaspiro[4,5]decan-2-one, a corticosteroid and/or a 5HT3 receptor antagonist and a chemotherapeutic agent to a patient in need of chemotherapy and treatment for chemotherapy-induced nausea and emesis.

18. The method of claim 17, wherein the corticosteroid is selected from dexamethasone and the 5HT3 antagonist is selected from the group consisting of ondansetron, granisetron, palonosetron, dolasetron or tropisetron.

19. The method of claim 17, wherein the pharmaceutical formulation comprises 5 to 200 mg of the crystalline hydrochloride monohydrate salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8- -phenyl-1,7-diazaspiro[4,5]decan-2-one.

20. The method of claim 19, wherein the pharmacokinetic (PK) profile of said 5-200 mg crystalline hydrochloride monohydrate salt in a patient in need of treatment thereof under single dose rising rate study conditions is: Cmax (ng/mL) 27.3 to 944 ng/mL; Tmax 2-4 hrs; AUC 931 to 148000 ng/hr/mL and Half Life T 1/2 (hours) 169-183 hrs.

21. A method of providing therapy to a patient in need of treatment for acute onset emesis and/or acute onset nausea comprising administration of an oral dosage form of a pharmaceutical formulation comprising 5-200 mg of a crystalline hydrochloride monohydrate salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-ph- enyl-1,7-diazaspiro[4,5]decan-2-one.

22. The method of claim 21 wherein the oral dosage form is a tablet or a capsule.

23. The method of claim 22 wherein the oral dosage form is a tablet.

24. The method of claim 23, wherein the tablet comprises 200 mg of the crystalline hydrochloride monohydrate salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-ph- enyl-1,7-diazaspiro[4,5]decan-2-one.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc